Blockchain Registration Transaction Record

Quantum BioPharma's Unbuzzd Appoints New CEO for Nasdaq Listing

Quantum BioPharma's Unbuzzd appoints Michael Zapolin as CEO to drive financing, Nasdaq listing, and U.S. rollout of its hangover-remedy beverage, unbuzzd.

The appointment of Michael Zapolin as CEO of Unbuzzd and the planned stock exchange listing signal a major step toward commercial expansion for the hangover-remedy beverage. For Quantum BioPharma (QNTM), this could unlock significant royalty streams—starting at 7% of sales until $250 million is reached—and enhance the value of its 19.84% equity stake. As Unbuzzd ramps up marketing and distribution across the U.S., investors and consumers should watch for broader availability and potential revenue growth. The move also underscores the growing consumer demand for functional beverages that address alcohol's aftereffects, a market that could see increased competition and innovation.